An additional proposed mechanism of action of proteasome inhibitors in AML is the reduction of constitutive nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signalling, particularly in leukemic stem cells (LSCs) [23, 24]. The gene discussed is NFKB1; the disease is acute myeloid leukemia.